Landscapes / Companies
Tyra Biosciences, Inc not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
3
in active trials
Trials
7 active
7 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Phase 2 | Nov 2026soonPhase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | FGFR3 Gene Mutation, FGFR3 Gene Alteration and 18 more | ||||
| Open drug page | |||||
— |
Phase 1 | Mar 2027Phase 1 trial completes | |||
| Next date | Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Jan 2028Phase 1 trial completes | |||
| Next date | Jan 2028 · Phase 1 trial completes | ||||
| Also tested for | Metastatic Hepatocellular Carcinoma, Solid Tumors and 9 more | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021